First-line treatment with pulsed field ablation (PFA) reduced the risk of recurrence of atrial arrhythmia among patients with persistent atrial fibrillation (Afib), the randomized AVANT GUARD trial ...
A minimally invasive heart procedure may be a better first-line treatment than medication for people living with advanced ...
Real-world data presented at HRS 2026 add to the body of evidence supporting a shift away from short-duration Holter monitoring toward up to 14 ...
There are both clinical and economic implications, as payers have been discouraging ablation in this population, one expert ...
New data on the pulsed-field ablation (PFA) device class debuts at HRS 2026 as the field catches the eye of several large medtech companies.
Should the transaction complete, J&J will inherit Atraverse’s radiofrequency system for simplifying access to the heart’s left atrium.
Rhythm (Nasdaq:IRTC) today announced findings from two real-world analyses supporting its long-term heart monitoring ...
Guidelines recommend a trial of antiarrhythmic drugs before catheter ablation for persistent atrial fibrillation. Whether pulsed field ablation (PFA) may be a preferred initial treatment is ...
Boston Scientific, Abbott and Medtronic shared new cardiac device data at the annual Heart Rhythm Society meeting, where ...
Adagio Medical (Nasdaq:ADGM) today announced new six-month results from its FULCRUM-VT clinical trial evaluating its ablation ...
CHICAGO, IL—When patients stop taking oral anticoagulation (OAC) after they’ve been free of atrial fibrillation (AF) ...
Adagio Medical Holdings, Inc. (Nasdaq: ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results